Skip to content

To Study the Clinical Course and Outcomes of Non-electively Hospitalised Patients of Chronic Liver Disease (CLD) With Hepatic or Extra-hepatic Predominant Organ Failure(s) at 6 Months.

To Study the Clinical Course and Outcomes of Non-electively Hospitalised Patients of Chronic Liver Disease (CLD) With Hepatic or Extra-hepatic Predominant Organ Failure(s) at 6 Months.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07270809
Enrollment
100
Registered
2025-12-08
Start date
2025-04-15
Completion date
2026-12-31
Last updated
2026-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Liver Disease

Brief summary

Title - To study the clinical course and outcomes of non-electively hospitalised patients of chronic liver disease (CLD) with Hepatic or Extra-hepatic predominant organ failure(s) at 6 months. Summary - ACLF is a condition where acute insult leading to worsening liver failure with or without extra-hepatic failure leads to a high short-term mortality. However, the presence of cirrhosis, prior decompensation, non-hepatic/systemic acute insult, organ failure and treatment are different in different part of the world. This is due to in-homogenous patient cohort. The current study was planned for all patients of CLD, who were non-electively hospitalized and were followed up for long-term to identify the differences in clinical course, acute insult, organ failure, therapy and outcome in relation to liver failure with or without extra-hepatic organic failure. In the study the laboratory, clinical parameters, inflammatory and regenerative markers will be evaluated as a marker of disease progression, reversal, recompensation or regression. This will enable us to differentiate the ACLF between east and west, guide us for defining the natural course of CLD with failure.

Interventions

OTHERNo Intervention

No Intervention

Sponsors

Institute of Liver and Biliary Sciences, India
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Age 18-70 years 2. CLD with or without cirrhosis with 1st or subsequent admissions for decompenasation and irrespective of any prior decompensation 3. Non-electively hospitalized

Exclusion criteria

1. HCC 2. NCPF/EHPVO 3. Pregnancy 4. Post-Liver transplant

Design outcomes

Primary

MeasureTime frame
Death or liver transplant at 6 months follow up.6 months

Secondary

MeasureTime frame
Recovery as per disease severity scores, i.e- decrease in MELD ≥5 and CTP ≥36 months
Organ dysfunction and organ failuresday 28, day 90, day 180

Countries

India

Contacts

CONTACTDr Amanjot Kaur, MD
amanjotbahri@gmail.com01146300000
CONTACTDr Ashok Chaoudhury, DM
doctor.ashokchoudhury@gmail.com01146300000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 12, 2026